STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

Pre-Mkt 08-28 07:19:03 EDT

49.22

-0.13

-0.26%

High49.81	Low48.50	Vol318.92K
Open49.61	D1 Closing49.35	Amplitude2.65%
Mkt Cap3.51B	Tradable Cap2.69B	Total Shares71.31M
T/O15.72M	T/O Rate0.58%	Tradable Shares54.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":49.22,"timestamp":1787860800000,"preClose":49.35,"halted":0,"volume":318921,"delay":0,"changeRate":-0.0026342451874367284,"floatShares":54641899,"shares":71309857,"eps":-3.1128,"marketStatus":"Pre-Mkt","change":-0.13,"latestTime":"08-28 07:19:03 EDT","open":49.61,"high":49.81,"low":48.5,"amount":15716432.620578,"amplitude":0.026545,"askPrice":56.44,"askSize":100,"bidPrice":46,"bidSize":19,"shortable":3,"etf":0,"ttmEps":-3.1128,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787923800000},"marketStatusCode":1,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":49.22,"postHourTrading":{"tag":"盘后","latestPrice":49.22,"preClose":49.22,"latestTime":"19:30 EDT","volume":21986,"amount":1082006.06,"timestamp":1787873404582,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.37563859652827786,"impliedVol":0.9832,"impliedVolPercentile":0.852},"requestUrl":"/m/hq/s/GPCR","defaultTab":"news","newsList":[{"id":"2662734860","title":"Press Release: Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662734860","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662734860?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:01","pubTimestamp":1787659260,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4599","GPCR","BK4007","BK4022","BK4232","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660719314","title":"Structure Therapeutics CSO Lin Xichen Reports Disposal of Common Shares Worth $207,378.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2660719314","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660719314?lang=en_us&edition=fundamental","pubTime":"2026-08-20 08:23","pubTimestamp":1787185428,"startTime":"0","endTime":"0","summary":"Structure Therapeutics CSO Lin Xichen reports disposal of common shares worth $207,378.61Structure Therapeutics Chief Scientific Officer Lin Xichen exercised share options for 11,817 ordinary shares a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDLbzMLt1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Structure Therapeutics CSO Lin Xichen Reports Disposal of Common Shares Worth $207,378.61","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658411956","title":"Press Release: Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658411956","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658411956?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:01","pubTimestamp":1786392060,"startTime":"0","endTime":"0","summary":"-- Septerna's Phase 1 clinical trial of SEP-479, a potent, selective. oral small molecule PTH1R agonist for the treatment of. serum calcium and endogenous serum PTH) in healthy volunteers.-- Based on pharmacokinetic data from the ongoing Phase 1 clinical. trial, the observed elimination half-life of SEP-479 is. approximately three to four days, which the Company anticipates. will support once-daily dosing. To fully characterize steady-state. pharmacokinetics, dosing for the MAD cohorts will be extended to. 14 days. As a result, Septerna expects to report Phase 1 data from. both the SAD and MAD cohorts in the first quarter of 2027.-- During the quarter, the Company presented the first detailed. preclinical characterization of SEP-479 in an oral presentation at. ENDO 2026, highlighting data supporting its potential as a. -- As reported in March 2026, SEP-631, an oral small molecule MRGPRX2","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4599","R","BK4022","BK4097","PRGS","BK4007","GPCR","LU2065732104.USD","SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626045","title":"Advancing Oral GLP‑1 and Amylin Pipeline Supports GPCR Buy Rating with Maintained $70 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626045","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626045?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:28","pubTimestamp":1786134487,"startTime":"0","endTime":"0","summary":"Analyst Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR and keeping the price target at $70...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/advancing-oral-glp1-and-amylin-pipeline-supports-gpcr-buy-rating-with-maintained-70-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/advancing-oral-glp1-and-amylin-pipeline-supports-gpcr-buy-rating-with-maintained-70-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR","GLP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626825","title":"Structure Therapeutics Chief Commercial Officer John Joseph Berrios Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626825","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626825?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:07","pubTimestamp":1786133263,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Chief Commercial Officer John Joseph Berrios files initial beneficial ownership statementStructure Therapeutics filed a Form 3 for Chief Commercial Officer John Joseph Berrios, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL21XJ5k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657566647","title":"Piper Sandler Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657566647","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657566647?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:27","pubTimestamp":1786116471,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $93.00. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DIVL","SAPH","APIE","GPCR","ARMH","CVY","DINT","AADR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666456","title":"Structure Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666456","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666456?lang=en_us&edition=fundamental","pubTime":"2026-08-07 07:41","pubTimestamp":1786059693,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. reports results for the quarter ended June 30 - Earnings SummaryStructure Therapeutics Inc.GPCR.OQreported a quarterly adjusted loss of 49 cents per share for the quarter e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663595","title":"Structure Therapeutics Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663595","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663595?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:45","pubTimestamp":1786049151,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Q2 net loss widens on higher R&D costsOverviewBiopharmaceutical firm's Q2 net loss widened as operating expenses rose on clinical trial costsCompany dosed first patients in Phas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657573046","title":"Structure Therapeutics Inc. Q2 Net Income USD -106.159 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657573046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657573046?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046712,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXXNQV5G:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661494","title":"Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661494","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661494?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist)Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340722/0/en/Structure-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GPCR","BK4009","MEDX","IDNA","LU0823414478.USD","GDOC","LENZ","HYLG","LU2357125470.USD","LU2249611893.SGD","CCO","BK4539","LU0823414551.USD","LU2294711713.HKD","JDOC","BMED","LU2506951792.HKD","BK4007","BK4599","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656374662","title":"Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2656374662","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656374662?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:24","pubTimestamp":1785763440,"startTime":"0","endTime":"0","summary":"WILMINGTON, Del., Aug.  03, 2026  (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Ther","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337599/33289/en/Exicure-to-Settle-GPCR-Therapeutics-Clinical-Milestone-Payment-Through-Equity-Issuance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4215","BK4585","GPCR","BK4588","REZ","BK4599","EQR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651491162","title":"Structure Therapeutics CSO Lin Xichen Disposes of USD 401,255.43 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2651491162","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651491162?lang=en_us&edition=fundamental","pubTime":"2026-07-16 06:58","pubTimestamp":1784156312,"startTime":"0","endTime":"0","summary":"Structure Therapeutics CSO Lin Xichen disposes of USD 401,255.43 in common sharesStructure Therapeutics Chief Scientific Officer Lin Xichen cut direct ordinary share holdings to 228,960 on July 14.Lin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL3jwSsc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Structure Therapeutics CSO Lin Xichen Disposes of USD 401,255.43 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649402939","title":"Race to Launch Weight-loss Pills Heats up as Smaller Players Advance","url":"https://stock-news.laohu8.com/highlight/detail?id=2649402939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649402939?lang=en_us&edition=fundamental","pubTime":"2026-07-08 00:12","pubTimestamp":1783440755,"startTime":"0","endTime":"0","summary":"FACTBOX-Race to launch weight-loss pills heats up as smaller players advanceAdds details of Kailera Therapeutics' obesity drug in paragraphs 1,2 and 25July 7 (Reuters)-Kailera Therapeutics'KLRA.Ooral ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4N4391DU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","LU1066053197.SGD","LU0708994859.HKD","LU0211331839.USD","LU0354030511.USD","LU2097828557.USD","LU1035773651.USD","BK4550","LU0345770993.USD","LU0210536198.USD","LU0106261372.USD","HRTS","LU2471134796.USD","LU1969619763.USD","LU2360032135.SGD","SG9999014914.USD","LU1430594728.SGD","IE00BFSS8Q28.SGD","MRK","LU1061106388.HKD","LU2023251221.USD","LU0965509010.AUD","LU1280957306.USD","BK1589","LU0306806265.USD","LU1814569148.SGD","LU0985481810.HKD","LU1093756325.SGD","LU2602419157.SGD","SG9999015978.USD","SG9999001440.SGD","LU0238689110.USD","LU0943347566.SGD","NVOH","LU1720051108.HKD","LU2491050154.USD","LU0130517989.USD","LU2361045086.USD","LU2471134952.CNY","LU2264538146.SGD","LU0058720904.USD","IXJ","LU1116320901.HKD","SG9999015952.SGD","LU2552382215.SGD","LU1023059063.AUD","LU0256863902.USD","IE00BFTCPJ56.SGD","LU0466842654.USD","LU2097828714.EUR","BK4568","LU0882574055.USD","LU2097828805.USD","PAWZ","LU0477156953.USD","LU2237443622.USD","IHE","LU2168564495.EUR","LU0820561909.HKD","BK4581","LU2125909593.SGD","SGXZ99366536.SGD","LU1917777945.USD","LU2357305700.SGD","01801","LU0859254822.USD","LU2125154778.USD","SGXZ31699556.SGD","LU1066051811.HKD","LU0109394709.USD","LU1037948897.HKD","RXL","LU1868836757.USD","SG9999014575.USD","LU0094547139.USD","IE0005OL40V9.USD","LU2746668974.SGD","LU0985320562.USD","LU0689472784.USD","BK4139","LU2097828631.EUR","IE00B19Z3581.USD","LU0432979614.USD","LU2491050071.SGD","IE00BK4W5M84.HKD","BK1574","LU0316494557.USD","IE00BKPKM429.USD","LU2237443382.USD","LU0786609619.USD","GDOC","LU2750360997.AUD","LU1989771016.USD","LU2168564222.USD","BK1161","LU0133085943.USD","LU0787776722.HKD","LU0823416689.USD","LU1267930573.SGD","LU0170899867.USD","LU0648001328.SGD","LU2756315318.SGD","IE00B1BXHZ80.USD","IE00BKDWB100.SGD","LU1894683348.USD","LU2111349929.HKD","LU1571399168.USD","NVO","LU0029864427.USD","LU1934455194.USD","LU0708995401.HKD","CANC","GB00BDT5M118.USD","LU0310800379.SGD","LU2237438978.USD","ELIS","LU0266013472.USD","LU0109391861.USD","IE0002270589.USD","FHLC","LU1629891620.HKD","LU2125154935.USD","LU0640476718.USD","LU2596442595.SGD","IE000M9KFDE8.USD","LU0158827781.USD","LU0345770308.USD","IE00BJJMRX11.SGD","LU2236285917.USD","SG9999014898.SGD","LU0128525929.USD","LU0868494617.USD","LU1093756168.USD","LU1585245621.USD","LU2211815571.USD","LU0456855351.SGD","LU1941712348.USD","ELIL","IE00B2B36J28.USD","LU0323591593.USD","LU2552382132.HKD","LU0502904849.HKD","HK0000165453.HKD","LU1868837136.USD","LU1974910355.USD","IE00BSNM7G36.USD","LU1037948541.HKD","LU2361044865.SGD","LU2023250330.USD","LU0203345920.USD","LU2265009873.SGD","LU2106854487.HKD","SG9999013999.USD","SG9999001176.SGD","LU2471134879.HKD","LU2756315664.SGD","IE00BZ1G4Q59.USD","LU0098860793.USD","LU0158827948.USD","LU2552382058.USD","SGXZ51526630.SGD","LU0070302665.USD","SG9999017495.SGD","LU1941712264.USD","IE00BLSP4452.SGD","LU1923622614.USD","IE00BJJMRY28.SGD","LU0289739699.SGD","LU0006306889.USD","LU0820561818.USD","LU0061475181.USD","LU0882574139.USD","BK1515","MEDI","IE0004445015.USD","LU2417539215.USD","LU2089284900.SGD","LU1934455863.HKD","SG9999014542.SGD","LU1232071149.USD","BK4534","LU2271345857.HKD","WDNA","BMED","LU2242644610.SGD","IE0001KFT4U8.USD","LU1323610961.USD","LU0823434740.USD","SG9999001176.USD","SG9999015358.SGD","LU1989772923.USD","BK4599","LU0868494708.USD","LU2360106947.USD","IE00BN29S564.USD","LU2089283258.USD","LU2168564149.EUR","LU0471298777.SGD","LU1894683264.USD","LU0942090050.USD","LU0306807586.USD","IE00BJJMRZ35.SGD","LU0114720955.EUR","IE00B4R5TH58.HKD","LU2237443895.HKD","LU1868836914.USD","LU1116320737.USD","LU1551013425.SGD","LU1929549753.HKD","SG9999015986.USD","LLYZ","LU0122379950.USD","SG9999014906.USD","LU0965509283.SGD","JDOC","LU0353189763.USD","BK4588","BK1583","LU0203347892.USD","LU2746668461.USD","LU2023250504.SGD","LU0321505439.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU0965508806.USD","LU0354030438.USD","LU0965509101.SGD","LU0225283273.USD","LU2087625088.SGD","LU0321505868.SGD","SG9999011175.SGD","LU0455707207.USD","IE0002141913.USD","LU1201861249.SGD","LU2108987350.USD","LU0320765646.SGD","LLII","KLRA","AGNG","LU0980610538.SGD","LU2468319806.SGD","IE00BJLML261.HKD","KURE","LU1551013342.USD","SG9999018865.SGD","SG9999018857.SGD","LU0353189680.USD","MEDX","LU0385154629.USD","LU1720051017.SGD","LU1989772840.SGD","LU1066051225.USD","OZEM","LU0154236417.USD","LU2237443978.SGD","LU2896262040.SGD","LU1267930730.SGD","LU1366192091.USD","LU1162221912.USD","LU2097828474.EUR","LU0096364046.USD","SGXZ81514606.USD","NVOX","LU1988902786.USD","SG9999015945.SGD","SG9999014559.SGD","LU0672654240.SGD","LU1127390331.HKD","IE0004445239.USD","LU0265550946.USD","LLY","LU0203201768.USD","ILDR","LU2237443465.HKD","SG9999002224.SGD","LU2213496289.HKD","LU1983299246.USD","LLYX","SG9999014567.USD","VKTX","LU1069344957.HKD","LU2324357040.USD","LU0130102774.USD","LU2462157665.USD","SG9999015341.SGD","LU0320765059.SGD","IE00BFSS7M15.SGD","LU0198837287.USD","01672","LU2361044949.HKD","AZN","LU2237443549.SGD","IE00BK4W5L77.USD","LU2023250843.SGD","LU0097036916.USD","LU1712237335.SGD","LU1868837300.USD","LU2491049909.HKD","IE00B3T34201.USD","LU0823434583.USD","LU1064131342.USD","LU1035775433.USD","LU2168563687.JPY","LU2461242641.AUD","IE00B7KXQ091.USD","LU1145028129.USD","GPCR","LU0234572021.USD","LU2168564065.EUR","LU0225771236.USD","LU1804176565.USD","LU1066051498.USD","LU0256863811.USD","LU2488822045.USD","FTXH","IE0009355771.USD","LU1829250122.USD","LU1548497426.USD","LU0320765489.SGD","THNR","IE00BLSP4239.USD","LU0417517546.SGD","AZNH","IE00B1XK9C88.USD","CURE","IE00BBT3K403.USD","LU2357627491.SGD","LU0208291251.USD","LU0225284248.USD","LU2089984988.USD","LU2471134523.USD","LU1883839398.USD","LU2433249047.HKD","SG9999003800.SGD","BK4592","LU2456880835.USD","PFE","BK4516","LU0889565916.HKD","SG9999014880.SGD","IYH","LU0265550359.USD","PJP","LU2112291526.USD","IE00BKVL7J92.USD","VHT","LU0320765992.SGD","LU0683600562.USD","BK4559","LU0964807845.USD","LU2028103732.USD","BK4585","LU0203202063.USD","LU1069347547.HKD","LU2063271972.USD","SGXZ57979304.SGD","IE00BWXC8680.SGD","LU1623119135.USD","LU0861579265.USD","IE00B4JS1V06.HKD","BK4532","LU2750360641.GBP","SG9999002232.USD","LU2125909247.SGD","XLV","IE00B775H168.HKD","BK4007","BK4533","IE00BN8TJ469.HKD","LU1868836591.USD","IE00B19Z3B42.SGD","LU0079474960.USD","LU1934455277.USD","LU0820562030.AUD","LU2328871848.SGD","LU1291159041.SGD","PPH","LU0471298694.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111335248","title":"Trump’s FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?","url":"https://stock-news.laohu8.com/highlight/detail?id=1111335248","media":"Macro World","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111335248?lang=en_us&edition=fundamental","pubTime":"2026-07-06 11:39","pubTimestamp":1783309194,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"37c8d9de4cc74b718092c554f88a5cc4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELIS","PFE","ELIL","RHHBY","LLY","AMGN","LLYX","GPCR","NVOH","NVOX","LLII","NVO","VKTX","LLYZ"],"isVideo":true,"video":{"duration":74,"video_url":"https://1254107296.vod2.myqcloud.com/e2ad4227vodcq1254107296/9044a4515001834810501024972/MWrOTca1gokA.mp4","video_thumbnail":"https://community-static.tradeup.com/news/42e81e07ef6b910080850b2d9b343c60","audio_url":"","isAI":true},"gpt_icon":0},{"id":"2644672036","title":"Structure Therapeutics shareholders elect directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2644672036","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644672036?lang=en_us&edition=fundamental","pubTime":"2026-06-19 04:06","pubTimestamp":1781813185,"startTime":"0","endTime":"0","summary":"Structure Therapeutics held its annual shareholder meeting on June 17, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL8tXw4y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643788133","title":"Why Structure Therapeutics (GPCR) Is Up 13.7% After Phase 2b Obesity Data Hit Nature Medicine And ADA","url":"https://stock-news.laohu8.com/highlight/detail?id=2643788133","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643788133?lang=en_us&edition=fundamental","pubTime":"2026-06-16 01:16","pubTimestamp":1781543787,"startTime":"0","endTime":"0","summary":"Structure Therapeutics announced that Phase 2b ACCESS trial results for its oral GLP-1 receptor agonist aleniglipron in people with overweight or obesity were published in Nature Medicine and presented at the American Diabetes Association’s 86th Scientific Sessions, showing statistically significant efficacy across three maintenance doses and a safety profile consistent with the GLP-1 class.\nThe interim open-label extension data, indicating durable weight loss beyond 36 weeks and improved...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/why-structure-therapeutics-gpcr-is-up-137-after-phase-2b-obe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/why-structure-therapeutics-gpcr-is-up-137-after-phase-2b-obe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643524302","title":"XtalPi Biopharma GPCR Pact Tests AI Drug Discovery And Revenue Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2643524302","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643524302?lang=en_us&edition=fundamental","pubTime":"2026-06-14 09:21","pubTimestamp":1781400115,"startTime":"0","endTime":"0","summary":"XtalPi Holdings (SEHK:2228) has entered a new partnership with a major international biopharma company to develop oral small molecule drugs targeting a complex GPCR.\nThe collaboration uses XtalPi's AI and quantum physics platforms, combined with automated labs, to work on challenging GPCR targets.\nThe deal carries a potential value of more than US$400 million, reflecting meaningful commercial scope for XtalPi's technology.\n\nXtalPi Holdings trades at HK$7.04, with the share price down 6.0%...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2228/xtalpi-holdings-shares/news/xtalpi-biopharma-gpcr-pact-tests-ai-drug-discovery-and-reven","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2228/xtalpi-holdings-shares/news/xtalpi-biopharma-gpcr-pact-tests-ai-drug-discovery-and-reven","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AGIX","AIPO","GPCR","CHAT","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642443650","title":"Nxera Pharma Joins OpenFold AI Consortium to Boost GPCR Drug Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2642443650","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642443650?lang=en_us&edition=fundamental","pubTime":"2026-06-10 14:58","pubTimestamp":1781074702,"startTime":"0","endTime":"0","summary":"Sosei Group ( ($JP:4565) ) just unveiled an update. Nxera Pharma, a biopharma specialist in GPCR structure-based drug discovery, has built a Japan-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nxera-pharma-joins-openfold-ai-consortium-to-boost-gpcr-drug-discovery?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nxera-pharma-joins-openfold-ai-consortium-to-boost-gpcr-drug-discovery?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIX","ARTY","AIPO","GPCR","CHAT","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642951064","title":"XtalPi Strikes US$400 Million GPCR Drug Discovery Pact with Global Biopharma Partner","url":"https://stock-news.laohu8.com/highlight/detail?id=2642951064","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642951064?lang=en_us&edition=fundamental","pubTime":"2026-06-09 22:41","pubTimestamp":1781016113,"startTime":"0","endTime":"0","summary":"QuantumPharm, Inc. ( ($HK:2228) ) has provided an update. XtalPi Holdings Limited has entered a strategic partnership with a leading international ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xtalpi-strikes-us400-million-gpcr-drug-discovery-pact-with-global-biopharma-partner?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xtalpi-strikes-us400-million-gpcr-drug-discovery-pact-with-global-biopharma-partner?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117976358","title":"XTALPI Forges Strategic AI Drug Discovery Alliance Valued Over $400M with Global Pharma Leader for Oral GPCR Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1117976358","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117976358?lang=en_us&edition=fundamental","pubTime":"2026-06-09 22:40","pubTimestamp":1781016053,"startTime":"0","endTime":"0","summary":"XTALPI (ASX: 02228) has announced a significant strategic collaboration with a prominent international biopharmaceutical company. The partnership is centered on the joint development of a novel oral...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228","BK4007","CHAT","BK1141","AGIX","BK4599","AIPO","GPCR","BK1617","ARTY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.structuretx.com","stockEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":0.0278},{"period":"3month","weight":0.2511},{"period":"6month","weight":-0.2185},{"period":"1year","weight":1.5905},{"period":"ytd","weight":-0.2923}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0408},{"period":"3month","weight":0.0193},{"period":"6month","weight":0.1241},{"period":"1year","weight":0.1925},{"period":"ytd","weight":0.1308}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.149001},{"month":2,"riseRate":0,"avgChangeRate":-0.188474},{"month":3,"riseRate":0.25,"avgChangeRate":-0.12966},{"month":4,"riseRate":0.5,"avgChangeRate":0.102223},{"month":5,"riseRate":0.25,"avgChangeRate":-0.029871},{"month":6,"riseRate":0.75,"avgChangeRate":0.191173},{"month":7,"riseRate":0,"avgChangeRate":-0.102138},{"month":8,"riseRate":0.75,"avgChangeRate":-0.026492},{"month":9,"riseRate":1,"avgChangeRate":0.463472},{"month":10,"riseRate":0.666667,"avgChangeRate":0.200398},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.123384},{"month":12,"riseRate":0.333333,"avgChangeRate":0.164068}],"exchange":"NASDAQ","name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","nameEN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","securityTypeName":"DR","adrRate":"1:3"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD,GPCR,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎国际,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股价,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股市,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票价格,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票交易,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票购买,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction